Prostate cancer: BRCA2 carriers respond to platinum-based chemotherapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In men with castration-resistant prostate cancer (PCa), breast cancer 2 (BRCA2) carriers showed an improved response to platinum-based chemotherapy compared with non-carriers.

Why this matters

  • BRCA2-associated breast and ovarian cancers are sensitive to platinum-based chemothera...